Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
bioAffinity Technologies Inc.
BIAF | US
1.04
USD0.01
0.97%
BIAF | US
About bioAffinity Technologies Inc.
Sector
Healthcare
Industry
Diagnostics & Research
Earnings date
30/06/2024
As of date
06/03/2026
Close
1.04
Open
1.00
High
1.05
Low
0.99
bioAffinity Technologies Inc. a biotechnology company engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung a diagnostic test for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio Texas.
View LessBIAF | US
Risk
154.0
Sharpe
-0.27
Luna's Score
43/100
Recommendation
Sell
Luna says (BIAF | US)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
145.0%1 month
154.0%3 months
111.8%6 months
165.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
5.54
Debt to equity
0.40
Debt to assets
0.21
Ent. to EBITDA
-0.21
Ent. to rev.
2.68
PEG
-
Other Fundamentals
EBITDA
-8.03M
MarketCap
14.03M
MarketCap(USD)
14.03M
Div. yield
-
Op. margin
-87.08
Erngs. growth
-
Rev. growth
12.05K
Ret. on equity
-151.52
Short ratio
4.32
Short perc.
5.25
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.27
Range1M
0.70
Range3M
1.10
Volumes: Market Activity
Rel. volume
0.33
Price X volume
86.88K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.21 | - | Cheaper |
| Ent. to Revenue | 2.68 | - | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 5.54 | 77.50 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 111.77 | - | Riskier |
| Debt to Equity | 0.40 | -14.36 | Expensive |
| Debt to Assets | 0.21 | 0.34 | Cheaper |
| Market Cap | 14.03M | - | Emerging |
